Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 6-K Current report (foreign)
- 99.1 Notice and Proxy Statement with Respect to the Company's Annual General Meeting of Shareholders
- 99.2 Proxy Card for Holders of Ordinary Shares with Respect to the Company's Annual General Meeting of Shareholders
- 99.3 Voting Instruction Card for American Depositary Share Holders with Respect to the Company's Annual General Meeting of Shareholders
CANF similar filings
- 23 Aug 22 Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver
- 22 Aug 22 Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
- 17 Aug 22 Report of Foreign Private Issuer
- 25 Jul 22 Report of Foreign Private Issuer
- 11 Jul 22 Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
- 29 Jun 22 Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis
- 24 Jun 22 Report of Foreign Private Issuer
Filing view
External links
Exhibit 99.3
